1), indicating that the treatment effect was consistent across calcium or vitamin D supplement levels. Fig. 2 Mean percent change from baseline ± SE in BMD over 1 year in women receiving risedronate 5 mg IR daily , 35 mg DRFB weekly , or 35 mg DRBB weekly . The Endpoint value is calculated using LOCF at Week 52. Asterisk statistically significant difference between IR daily and each of the DR weekly treatment groups Significant increases from baseline in BMD at sites in the hip (total proximal femur, femoral neck, femoral trochanter) were observed at 26 and 52 weeks and Endpoint in

all treatment groups (Fig. 2). As was the case for lumbar spine BMD, there were no statistically significant differences between either of the DR weekly regimens and the IR daily regimen at any time point Fosbretabulin concentration for the total proximal femur and the femoral trochanter. At the femoral neck, no statistically significant differences were seen between the DR FB weekly and the IR daily groups

at any time point; however, statistically greater increases in BMD at Week 52 and Endpoint were seen in the DR BB weekly group compared to the IR daily group (least squares mean difference in percent change from baseline at Endpoint = −0.537; 95% CI −1.000, −0.074). Significant decreases from baseline in NTX/creatinine, CTX, and BAP were observed at 13, 26, and 52 weeks in all treatment groups CP-690550 concentration (Fig. 3). Small differences were observed in the responses of resorption markers between the DR weekly groups and the IR daily group. Compared to the IR daily regimen, the decrease in urinary NTX/creatinine was statistically greater with DR FB weekly dosing at Week 52 and Endpoint, and the reduction in serum CTX was significantly greater in the DR FB weekly group at Weeks 26 and 52 and at Endpoint and with ID-8 the DR BB dose at Endpoint. Fig. 3 Mean percent change from baseline ± SE in bone turnover markers over 1 year in women receiving risedronate 5 mg IR daily

, 35 mg DRFB weekly , or 35 mg DRBB weekly . The Endpoint value is calculated using LOCF at Week 52. Asterisk statistically significant difference between IR daily and each of the DR weekly treatment groups New find more incident morphometric vertebral fractures during the first 52 weeks of treatment occurred in two subjects in the IR daily group, 2 subjects in the DR FB weekly group, and 3 subjects in the DR BB weekly group. There were no statistically significant differences between either of the DR weekly groups and the IR daily group. Safety assessments Overall, the adverse event profile was similar across the three treatment groups during the first 52 weeks of treatment (Table 2). The incidence of upper gastrointestinal adverse events was numerically but not significantly higher in the DR BB weekly group than in the IR daily or DR FB weekly groups, mostly due to a significantly higher incidence of upper abdominal in the DR BB group (p value = 0.0041). These events were all judged to be mild or moderate.